Myocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021)

doi:10.1016/j.hlc.2022.02.002

Heart, Lung and Circulation

Volume 31, Issue 6, June 2022, Pages 757-765

https://doi.org/10.1016/j.hlc.2022.02.002 Get rights and content

Introduction

Reports of SARS-CoV-2 coronavirus (COVID-19) vaccine-related myocarditis, particularly after mRNA vaccines, have raised concerns amongst the general public. This review examined the literature regarding myocarditis post COVID-19 vaccination, drawing from vaccine safety surveillance databases and case reports.

Methods

Combinations of search terms were used in PubMed and COVID-19-specific repositories – LitCovid and the Cochrane COVID-19 Study Register – between 1 October 2020 and 31 October 2021. Manual searches of GoogleScholar and screening of article bibliographies were also performed.

Results

Information was obtained from five vaccine safety surveillance databases. Fifty-two (52) case reports totalling 200 cases of possible COVID-19 vaccine-related myocarditis were summarised. Vaccine surveillance databases differed in reporting formats and vaccination rates; however, gross estimates suggested low overall incidence rates of 2–5 per million mRNA vaccines. The incidence appeared to be higher in younger male populations, with onset of symptoms within a few days, usually after the second dose. Some with prior COVID-19 infections had onset after the first dose. Cases with prior unrelated myocarditis were also noted. Almost all presented with chest pain (98.0%). Troponin elevation was universally described and cardiac magnetic resonance imaging was commonly reported based on the updated Lake Louise criteria. Clinical course was mild in the majority, with response to anti-inflammatory treatment.

Conclusion

COVID-19 vaccine-related myocarditis is an important but rare adverse event. More research is needed into its pathogenesis and reasons for its predominance in young males, while gaps in data exist in those aged <16 years, as well as those with prior COVID-19 infections and prior myocarditis.

Introduction

As the pandemic caused by the SARS-CoV-2 coronavirus (COVID-19) continues, global efforts driving vaccinations are pivotal to restoring health and attempting economic and social recovery. In December 2020, the USA Food and Drug Administration (FDA) granted emergency authorisation for the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. In recent months, reports of myocarditis following COVID-19 vaccination, particularly after the messenger RNA (mRNA) vaccines, have received media publicity and raised concerns amongst the general public.

There is a pressing need for a better understanding of the available data, especially as several countries debate vaccination of adolescents in light of the concerns from the Omicron variant. This report reviews the current literature regarding myocarditis post COVID-19 vaccination, summarising both publicly available information from vaccine safety surveillance databases and published case reports, with particular attention to reporting rates, patient and disease characteristics, as well as investigation and treatment outcomes.

Section snippets

Methods

This review performed systematic searches of online databases, including PubMed and two COVID-19-specific databases (LitCovid [1] and the Cochrane COVID-19 Study Register) between 1 October 2020 and 31 October 2021. LitCovid was selected as a curated literature repository for articles on COVID-19 from PubMed [2]. The Cochrane COVID-19 Study Register was selected for comprehensiveness and accuracy, with multiple data sources cited, including PubMed and Embase.com [3]. The medical subjects

Vaccine Safety Surveillance Databases

The most commonly referenced vaccine safety surveillance databases were selected, these were: the World Health Organization (WHO) global database VigiBase [4], the USA Vaccine Adverse Event Reporting System (VAERS) [5], the UK Medicines and Healthcare Regulatory Agency (MHRA), and information from the Israeli Ministry of Health. These countries are amongst those that had relatively early and large-scale vaccination drives. Data from the Health Sciences Authority (HSA) of Singapore from the

Discussion

The reports of myocarditis post COVID-19 vaccines, particularly with mRNA vaccines, are a public safety concern. Myocarditis itself is usually idiopathic. If an identified cause is found, it is usually viral in aetiology [43]. Vaccine-related myocarditis is rare, with previous cases associated with the smallpox [44,45] and influenza [46,47] vaccines. The original clinical trials for these mRNA vaccines did not detect myocarditis [48,49], although there was one case of paroxysmal ventricular

Conclusion

As countries debate vaccination of younger adolescents and children, the public and healthcare professionals should be aware of the symptoms associated with COVID-19 vaccine-related myocarditis, but also that the overall risk appears low. However, further research into this condition is warranted, particularly regarding the pathogenesis and higher prevalence in younger males. There is also a current gap in understanding in a few population groups, including those aged <16 years, those with

Declarations of interest

None.

Funding sources

Nil.

References (65)

V.M. Ferreira et al.
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations
J Am Coll Cardiol
(2018)
Q. Chen et al.
Keep up with the latest coronavirus research
Nature
(2020)
Q. Chen et al.
LitCovid: An open database of COVID-19 literature
Nucleic Acids Res
(2021)
M.I. Metzendorf et al.
Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production
Res Synth Methods
(2021)
M. Lindquist
VigiBase, the WHO Global ICSR Database System: Basic facts
Drug Inf J
(2008)
T.T. Shimabukuro et al.
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Vaccine
(2015)
M. Kerneis et al.
COVID-19 vaccines and myocarditis
Arch Cardiovasc Dis
(2021)
A. Deb et al.
Acute myocardial injury following COVID-19 vaccination : a case report and review of current evidence from Vaccine Adverse Events Reporting System Database
J Prim Care Community Health
(2021)
J.W. Gargano et al.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices
MMWR Morb Mortal Wkly Rep
(2021)
H.G. Rosenblum et al.
Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021
MMWR Morb Mortal Wkly Rep
(2021)

Coronavirus vaccine - weekly summary of Yellow Card reporting. Med Healthc Prod Regul Agency

COVID-19 vaccines: updates for July 2021. Med Healthc Prod Regul Agency

Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (Including)

Health Sciences Authority S. HSA’s Safety Update #5 COVID-19 Vaccines (30 Dec 2020-31 Aug 2021)...

A. Ramírez-García et al.

Pericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19

Rev Española Cardiol

(2021)

M.K. Vidula et al.

Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines

Cureus

(2021)

S. Ashaari et al.

A case report: symptomatic pericarditis post-COVID-19 vaccination

Eur Hear J Case Rep

(2021)

S. Ambati et al.

Acute myopericarditis after COVID-19 vaccine in teenagers

Case Rep Cardiol

(2021)

J. Schauer et al.

Myopericarditis after the Pfizer messenger ribonucleic acid Coronavirus disease vaccine in adolescents

J Pediatr

(2021)

A. Dionne et al.

Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children

JAMA Cardiol

(2021)

B.B. Das et al.

Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far?

Child

(2021)

J. Montgomery et al.

Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military

JAMA Cardiol

(2021)

D. Levin et al.

Myocarditis following COVID-19 vaccination – A case series

Vaccine

(2021)

N. Gautam et al.

A late presentation of COVID-19 vaccine-induced myocarditis

Cureus

(2021)

C.M. Rosner et al.

Myocarditis temporally associated with COVID-19 vaccination

Circulation

(2021)

M. Nassar et al.

COVID-19 vaccine-induced myocarditis: case report with literature review

Diabetes Metab Syndr

(2021)

I. Sulemankhil et al.

Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review

Cardiovasc Revasc Med

(2021)

B. Chamling et al.

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?

Clin Res Cardiol

(2021)

K.E. Shaw et al.

Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings

JACC Cardiovasc Imaging

(2021)

J.B. Dickey et al.

A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2

JACC Cardiovasc Imaging

(2021)

K.F. Larson et al.

Myocarditis after BNT162b2 and mRNA-1273 vaccination

Circulation

(2021)

A.K. Verma et al.

Myocarditis after Covid-19 mRNA vaccination

N Engl J Med

(2021)

Cited by (17)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
2023, Journal of the Formosan Medical Association
MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.
This is a randomized, double-blind trial that recruited adults aged 20–70 years who previously received a single dose of mRNA-1273 vaccine and were randomly assigned in a 1:1 ratio to receive a second dose with the homologous vaccine or protein-based MVC-COV1901 8–12 weeks after the first dose. The primary outcome was neutralizing antibody titers in terms of the geometric mean titer (GMT) 14 days after the second dose. Safety was assessed in all participants who received a dose of the study vaccine. The study is registered with ClinicalTrials.gov (NCT05079633).
From September 30 to November 5, 2021, 144 participants were enrolled and randomly assigned to the MVC-COV1901 boost group (n = 72) or the mRNA-1273 boost group (n = 72). The neutralizing antibodies on Day 15 and the anti-SARS-CoV-2 IgG titers on Day 15 and 29 of homologous mRNA-1273 were significantly higher than those of heterologous mRNA-1273/MVC-COV1901. Cellular immune responses were comparable in both groups. However, adverse events were much more frequent after the mRNA-1273 boost than after the MVC-COV1901 boost.
Our results show that heterologous boost with MVC-COV1901 yielded an inferior immunogenicity but significantly fewer adverse events, compared with homologous boost with mRNA-1273. In people experienced severe adverse events after prime dose of mRNA-1273, as well as in periods when the supply of mRNA-1273 is limited, MVC-COV1901 could serve as an acceptable alternative heterologous boost.
BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
2023, Pediatrics and Neonatology
To investigate Pfizer-BioNTech 162b2 mRNA COVID-19 vaccine (BNT162b2) immunization-related myocarditis and describe the risk factors for consequent hospitalization in the pediatric intensive care unit (PICU) in children between 12 and 18 years.
Children and adolescents 12 years of age and older who presented with discomfort after BNT162b2 immunization (BNTI) and visited pediatric emergency room (PER) at Chang Gung Memorial Hospital from September 22, 2021 to March 21, 2022, were included for analysis.
681 children presented with discomfort after BNTI and visited our PER. The mean age was 15.1 ± 1.7 years. Three hundred and ninety-four (57.9%) and 287 (42.1%) events were after 1st and 2nd dose, respectively. 58.4% (n = 398) were male. The most common complaints were chest pain (46.7%) and chest tightness (27.0%). The median (interquartile range [IQR]) interval of discomfort after BNTI was 3.0 (1.0−12.0) days. BNTI-related pericarditis, myocarditis and myopericarditis were diagnosed in 15 (2.2%), 12 (1.8%) and 2 (0.3%) patients, respectively. Eleven (1.6%) needed hospitalization in PICU. The median (IQR) hospital stay was 4.0 (3.0−6.0) days. There was no mortality. More patients were diagnosed myocarditis (p = 0.004) after 2nd dose BNTI. PICU admission occurred more commonly after 2nd dose BNTI (p = 0.007). Risk factors associated with hospitalization in PICU were abnormal EKG findings (p = 0.047) and abnormal serum troponin levels (p = 0.003) at PER.
Myocarditis in children aged 12−18 years occurred more commonly following 2nd dose BNTI. Most cases were of mild or intermediate severity without death. Factors predicting BNTI-related myocarditis and consequent hospitalization in PICU were abnormal EKG findings and abnormal serum troponin levels at PER in this study.
Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
2022, Journal of the American College of Cardiology
Postmarketing evaluations have linked myocarditis to COVID-19 mRNA vaccines. However, few population-based analyses have directly compared the safety of the 2 mRNA COVID-19 vaccines.
This study aimed to compare the risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273.
We used data from the British Columbia COVID-19 Cohort (BCC19C), a population-based cohort study. The exposure was the second dose of an mRNA vaccine. The outcome was diagnosis of myocarditis, pericarditis, or myopericarditis during a hospitalization or an emergency department visit within 21 days of the second vaccination dose. We performed multivariable logistic regression to assess the association between vaccine product and the outcomes of interest.
The rates of myocarditis and pericarditis per million second doses were higher for mRNA-1273 (n = 31, rate 35.6; 95% CI: 24.1-50.5; and n = 20, rate 22.9; 95% CI: 14.0-35.4, respectively) than BNT162b2 (n = 28, rate 12.6; 95% CI: 8.4-18.2 and n = 21, rate 9.4; 95% CI: 5.8-14.4, respectively). mRNA-1273 vs BNT162b2 had significantly higher odds of myocarditis (adjusted OR [aOR]: 2.78; 95% CI: 1.67-4.62), pericarditis (aOR: 2.42; 95% CI: 1.31-4.46) and myopericarditis (aOR: 2.63; 95% CI: 1.76-3.93). The association between mRNA-1273 and myocarditis was stronger for men (aOR: 3.21; 95% CI: 1.77-5.83) and younger age group (18-39 years; aOR: 5.09; 95% CI: 2.68-9.66).
Myocarditis/pericarditis following mRNA COVID-19 vaccines is rare, but we observed a 2- to 3-fold higher odds among individuals who received mRNA-1273 vs BNT162b2. The rate of myocarditis following mRNA-1273 receipt is highest among younger men (age 18-39 years) and does not seem to be present at older ages. Our findings may have policy implications regarding the choice of vaccine offered.
Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis
2022, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
Citation Excerpt :
Cardiac-specific investigations revealed that troponin levels were elevated in almost all cases, consistent with myocardial injury, which is associated with autoimmune processes matched with vaccine protein and the case immune system. In the same lines as Lee et al. (2022) [1], a systematic review to investigate myocarditis following COVID-19 Vaccination in October 2020–October 2021, mentions that all reported cases have an elevated troponin level in keeping with myocardial injury. In our study, less than one third of cases had left ventricle ejection fraction (LVEF) was less than 50%.
Recent media reports of myocarditis after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines, are causing public concern. This review summarizes information from published case series and case reports, emphasizing patient and disease characteristics, investigation, and clinical outcomes, to provide a comprehensive picture of the condition.
A systematic literature search of PubMed and Google scholar was conducted from inception to April 27, 2022. Individuals who develop myocarditis after receiving the COVID-19 vaccine, regardless of the type of vaccine and dose, were included in the study.
Sixty-two studies, including 218 cases, participated in the current systematic review. The median age was 29.2 years; 92.2% were male and 7.8% were female. 72.4% of patients received the Pfizer-BioNTech (BNT162b2) vaccine, 23.8% of patients received the Moderna COVID-19 Vaccine (mRNA-1273), and the rest of the 3.5% received other types of COVID-19 vaccine. Furthermore, most myocarditis cases (82.1%) occurred after the second vaccine dose, after a median time interval of 3.5 days. The most frequently reported symptoms were chest pain, myalgia/body aches and fever. Troponin levels were consistently elevated in 98.6% of patients. The admission ECG was abnormal in 88.5% of cases, and the left LVEF was lower than 50% in 21.5% of cases. Most patients (92.6%) resolved symptoms and recovered, and only three patients died.
These findings may help public health policy to consider myocarditis in the context of the benefits of COVID-19 vaccination.
Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination
2023, Diabetology International
Viral Pneumonia during the COVID-19 Pandemic, 2019–2021 Evoking Needs for SARS-CoV-2 and Additional Vaccinations
2023, Vaccines

View all citing articles on Scopus

View full text

ReviewMyocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021)

Introduction

Methods

Results

Conclusion

Introduction

Section snippets

Methods

Vaccine Safety Surveillance Databases

Discussion

Conclusion

Declarations of interest

Funding sources

J Am Coll Cardiol

Keep up with the latest coronavirus research

Nature

LitCovid: An open database of COVID-19 literature

Nucleic Acids Res

Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production

Res Synth Methods

VigiBase, the WHO Global ICSR Database System: Basic facts

Drug Inf J

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

Vaccine

COVID-19 vaccines and myocarditis

Arch Cardiovasc Dis

Acute myocardial injury following COVID-19 vaccination : a case report and review of current evidence from Vaccine Adverse Events Reporting System Database

J Prim Care Community Health

Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices

MMWR Morb Mortal Wkly Rep

Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

MMWR Morb Mortal Wkly Rep

Coronavirus vaccine - weekly summary of Yellow Card reporting. Med Healthc Prod Regul Agency

COVID-19 vaccines: updates for July 2021. Med Healthc Prod Regul Agency

Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (Including)

Pericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19

Rev Española Cardiol

Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines

Cureus

A case report: symptomatic pericarditis post-COVID-19 vaccination

Eur Hear J Case Rep

Acute myopericarditis after COVID-19 vaccine in teenagers

Case Rep Cardiol

Myopericarditis after the Pfizer messenger ribonucleic acid Coronavirus disease vaccine in adolescents

J Pediatr

Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children

JAMA Cardiol

Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far?

Child

Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military

JAMA Cardiol

Myocarditis following COVID-19 vaccination – A case series

Vaccine

A late presentation of COVID-19 vaccine-induced myocarditis

Cureus

Myocarditis temporally associated with COVID-19 vaccination

Circulation

COVID-19 vaccine-induced myocarditis: case report with literature review

Diabetes Metab Syndr

Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review

Cardiovasc Revasc Med

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?

Clin Res Cardiol

Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings

JACC Cardiovasc Imaging

A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2

JACC Cardiovasc Imaging

Myocarditis after BNT162b2 and mRNA-1273 vaccination

Circulation

Myocarditis after Covid-19 mRNA vaccination

N Engl J Med

Review
Myocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021)